BRPI0407474A - Partìculas revestidas e formas de dosagem farmacêuticas - Google Patents

Partìculas revestidas e formas de dosagem farmacêuticas

Info

Publication number
BRPI0407474A
BRPI0407474A BR0407474-2A BRPI0407474A BRPI0407474A BR PI0407474 A BRPI0407474 A BR PI0407474A BR PI0407474 A BRPI0407474 A BR PI0407474A BR PI0407474 A BRPI0407474 A BR PI0407474A
Authority
BR
Brazil
Prior art keywords
dosage forms
pharmaceutical dosage
coated particles
coating
present
Prior art date
Application number
BR0407474-2A
Other languages
English (en)
Inventor
Vlasta Humar
Mateja Burjak
Rok Grahek
Mateja Salobir
Janez Kerc
Klemen Kocevar
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0407474A publication Critical patent/BRPI0407474A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PARTìCULAS REVESTIDAS E FORMAS DE DOSAGEM FARMACêUTICAS". A presente invenção refere-se as partículas revestidas e formas de dosagem farmacêuticas compreendendo as substâncias ativas sensíveis às influências ambientais. O revestimento da presente invenção fornece estabilidade e proteção da substância ativa em influências ambientais e em particular de oxidação e/ou umidade ambiental por revestimento.
BR0407474-2A 2003-02-12 2004-02-11 Partìculas revestidas e formas de dosagem farmacêuticas BRPI0407474A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200300041A SI21402A (sl) 2003-02-12 2003-02-12 Obloženi delci in farmacevtske oblike
PCT/SI2004/000009 WO2004071403A2 (en) 2003-02-12 2004-02-11 Coated particles and pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
BRPI0407474A true BRPI0407474A (pt) 2006-02-07

Family

ID=32867327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407474-2A BRPI0407474A (pt) 2003-02-12 2004-02-11 Partìculas revestidas e formas de dosagem farmacêuticas

Country Status (10)

Country Link
US (3) US20060093680A1 (pt)
EP (1) EP1594474B1 (pt)
AU (2) AU2004211887A1 (pt)
BR (1) BRPI0407474A (pt)
CA (1) CA2514720C (pt)
ES (1) ES2636537T3 (pt)
HU (1) HUE032956T2 (pt)
SI (1) SI21402A (pt)
WO (1) WO2004071403A2 (pt)
ZA (1) ZA200506240B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
NZ517663A (en) * 1999-08-16 2006-02-24 Revaax Pharmaceuticals Llc Neurotherapeutic clavulanate composition and method
UA78326C2 (uk) * 2002-06-12 2007-03-15 Сінгента Партісіпейшнс Аг Гербіцидна синергетична композиція та спосіб боротьби з ростом небажаної рослинності
WO2005004989A2 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
AU2005305460B2 (en) 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
DK1944029T3 (da) * 2005-10-31 2012-01-23 Kowa Co Farmaceutisk præparat med fremragende fotostabilitet
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
US7772273B2 (en) 2006-02-10 2010-08-10 Lifecycle Pharma A/S Stabilized atorvastatin
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
JPWO2008069262A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
WO2008098195A2 (en) * 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
KR20100101574A (ko) * 2007-10-26 2010-09-17 렉산 파마슈티컬스, 인코포레이티드 클라불란산의 제약 제제
EP2070520A1 (en) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
US20110027356A1 (en) * 2008-01-25 2011-02-03 Duo-Ge Combination of Oral Medicaments Bonded by a Wrapping
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
WO2009140341A2 (en) * 2008-05-13 2009-11-19 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
CA2637977A1 (en) * 2008-07-15 2010-01-15 Pharmascience Inc. Dosage form containing a statin
EP2424498A1 (en) * 2009-04-29 2012-03-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US20110104277A1 (en) * 2009-10-30 2011-05-05 Ma Decheng Oxygen barrier film coatings for pharmaceutical dosage forms
EP2522348B1 (en) * 2009-12-25 2016-05-25 Sawai Pharmaceutical Co., Ltd. Atorvastatin-containing coated preparation
US9795576B2 (en) * 2010-09-27 2017-10-24 Basf Se Protective coatings for acidic active ingredients
EP2830782A4 (en) * 2012-03-26 2015-11-25 Univ California METHOD FOR AEROSOL COATING BASED ON NON-FLAMMABLE VOLATILE SOLVENTS
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
EP3106152B1 (en) * 2014-02-12 2021-02-17 Sawai Pharmaceutical Co., Ltd. Orally disintegrating tablet coated with film
EP3250225A1 (en) * 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN107485605A (zh) * 2017-08-02 2017-12-19 南京泽恒医药技术开发有限公司 一种磺胺嘧啶银喷膜剂及其制备方法
WO2019161402A1 (en) * 2018-02-19 2019-08-22 Sensient Colors Llc Compositions for coating edible substrates and methods of making and using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816061A (en) * 1954-05-27 1957-12-10 Univ Illinois Sodium carboxymethyl cellulose tablet coating
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4428926A (en) 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
KR100278498B1 (ko) 1991-10-07 2001-01-15 웨인 에이치. 피쳐 피복된 효소함유 과립
CZ297271B6 (cs) 1994-07-12 2006-10-11 Bpsi Holdings, Inc. Suchá povlaková hmota pro výrobu filmu zabranujícímu prístupu vlhkosti, zpusob a tvorba povlaku
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
CA2262595C (en) * 1996-08-15 2005-10-18 Losan Pharma Gmbh Easy to swallow oral medicament composition
ID21762A (id) 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
NZ520176A (en) 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
AU1534699A (en) * 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU764469B2 (en) 1999-01-29 2003-08-21 Disphar International B.V. Pharmaceutical compositions
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US20020086061A1 (en) * 1999-10-26 2002-07-04 Sharma Vinay K. Preparation of micron-size felodipine particles by microfluidization
EP1225880A2 (en) 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
AU2000701A (en) 1999-11-24 2001-06-04 Bayer Aktiengesellschaft Methods of ameliorating abnormal bone states
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399396A1 (en) 2000-02-10 2001-08-16 Yasuo Sugiyama Tnf- .alpha. inhibitors
US7081240B1 (en) 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
CA2417813A1 (en) * 2000-08-10 2002-02-21 Delsys Pharmaceutical Corporation Improved solid pharmaceutical dosage formulation of hydrophobic drugs
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
JP2005500307A (ja) * 2001-06-21 2005-01-06 アンドルックス ファーマスーティカルズ インコーポレーテッド プラバスタチンを含む安定な徐放性薬剤組成物
EP1624862B1 (en) * 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials

Also Published As

Publication number Publication date
US9149460B2 (en) 2015-10-06
US20060093680A1 (en) 2006-05-04
AU2011201400A1 (en) 2011-04-14
CA2514720A1 (en) 2004-08-26
US9907757B2 (en) 2018-03-06
US20160128946A1 (en) 2016-05-12
ZA200506240B (en) 2007-02-28
EP1594474A2 (en) 2005-11-16
AU2011201400B2 (en) 2011-06-23
US20080138429A1 (en) 2008-06-12
CA2514720C (en) 2013-05-14
EP1594474B1 (en) 2017-03-22
SI21402A (sl) 2004-08-31
WO2004071403A2 (en) 2004-08-26
AU2004211887A1 (en) 2004-08-26
ES2636537T3 (es) 2017-10-06
WO2004071403A3 (en) 2005-02-24
HUE032956T2 (hu) 2017-11-28

Similar Documents

Publication Publication Date Title
BRPI0407474A (pt) Partìculas revestidas e formas de dosagem farmacêuticas
PT1309503E (pt) Dispositivo medico de pulverizacao
FI973419A0 (fi) Epäorgaanisten aerogeelien käyttö lääkkeiden valmistuksessa
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
Chtourou et al. Improvement of cerebellum redox states and cholinergic functions contribute to the beneficial effects of silymarin against manganese-induced neurotoxicity
FR2856594B1 (fr) Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s)
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE295155T1 (de) Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
DE60014164D1 (de) Messung und kontrolle von sessiler und planktonischer mikrobiologischer aktivität in industriellen wassersystemen
CY1119242T1 (el) Αερολυμα περιεχον μια σωματιδιακη ενεργη ουσια
FR2842201B1 (fr) Nouvel oligosaccharide, compositions cosmetiques et/ou dermatologiques en contenant et ses applications
DE502006008194D1 (de) Erosoltherapie
EP1980244A3 (en) Basis particles and orally-disintegrating tablet containing them
ITTN20050005A1 (it) Procedimento chimico per la riduzione di vapori tossici ed irritanti causati da ammoniaca dall'utilizzo di creme coloranti o decoloranti i capelli.
WO2008087365A3 (fr) Derives de 1,3-diphenylpropane substitues, preparations et utilisations
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
WO2004071402A3 (en) STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
BR0314300A (pt) Aplicação de substâncias para a proteção da pele
FR2925500B1 (fr) Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
FR2834896B1 (fr) Composition pharmaceutique orodispersible d'ivabradine
PT1333797E (pt) Composicoes dentarias para dentes hipersensiveis
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
FR2875137B1 (fr) Dispositif de conditionnement de l'atmosphere par diffusion de substances aromatiques ou autres principes actifs volatils
SE0102910D0 (sv) New use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL